A

Amgen

Makes biotech medicines for serious illnesses

Encryption Agility Engineer

Full-TimeUpdated on 10/15/2026
No salary listed
Senior
Bachelor's, Master's, PhD, Associate's
Hyderabad, Telangana, India
In Person
CybersecuritySecurity Engineering & Architecture

About the job

Requirements
  • Doctorate degree in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related field, or a master's degree with 4 to 6 years of relevant experience, a bachelor's degree with 6 to 8 years of relevant experience, or a diploma with 10 to 12 years of relevant experience.
  • Strong hands-on knowledge of enterprise cryptography, including Public Key Infrastructure (PKI), X.509 certificates, Transport Layer Security (TLS), cipher suites, Key Management Services (KMS), Hardware Security Modules (HSMs), secrets management, key lifecycle, encryption at rest and in transit, cloud key services, identity protocols, and certificate lifecycle automation.
  • Practical experience with cryptographic discovery, Cryptographic Bill of Materials (CBOM)-driven inventory, source code scanning, network and endpoint telemetry, cloud key service analysis, false-positive triage, data quality controls, dashboards, and remediation tracking.
  • Working knowledge of post-quantum cryptography, crypto agility, National Institute of Standards and Technology (NIST)-approved algorithms and standards, hybrid transition patterns, Steal-Now-Decrypt-Later (SNDL) risk reduction, and risk-prioritized remediation.
  • Ability to convert cryptographic policy, architecture direction, and scan findings into actionable engineering guidance across Continuous Integration/Continuous Delivery (CI/CD), Secure Software Development Life Cycle (SSDLC), cloud platforms, PKI and certificates, KMS and secrets, identity, infrastructure, applications, third-party governance, and risk management.
  • Mandatory experience designing and implementing Artificial Intelligence (AI)-enabled process orchestration for security, cryptography, governance, risk, compliance, or technology operations workflows, including AI-agent or multi-agent patterns, reducing manual effort, improving analysis consistency and team throughput, and maintaining human-in-the-loop review for high-risk or decision-bearing activities.
  • Mandatory ability to architect AI agents to achieve defined service actions and outcomes, including workflow decomposition, agent role definition, tool and data-source integration, prompt and instruction design, validation checkpoints, exception handling, auditability, and escalation paths for human review.
  • Strong analytical, troubleshooting, and problem-solving skills; technical ownership to drive complex discovery, analysis, and remediation work to completion; verbal and written communication for technical, business, compliance, procurement, and vendor audiences; ability to translate cryptographic findings into risk statements, remediation options, and implementation steps; ability to influence across global stakeholder teams; initiative, accountability, judgment, and self-motivation; teamwork; coaching and mentoring; documentation, presentation, and knowledge-sharing; and ability to redesign manual workflows for automation and AI augmentation while balancing quality, accountability, and human judgment.
Responsibilities
  • Execute assigned Encryption Agility Service workstreams, including intake analysis, backlog execution, roadmap tracking, service metrics, reporting inputs, Standard Operating Procedure (SOP) updates, and service improvement actions under the direction of the Senior Manager and Principal Architect.
  • Operate enterprise cryptographic discovery across source code, binaries, cloud key services, endpoints, file systems, network traffic, PKI and certificates, KMS and secrets, vendor attestations, Software Bill of Materials (SBOM) inputs, and subject matter expert interviews.
  • Build, maintain, and improve the enterprise CBOM using CycloneDX 1.6+ as the target format, including required fields, source systems, ownership attributes, quantum-vulnerability status, remediation status, data quality checks, reporting views, and asset correlation.
  • Support tool integration and data normalization across enterprise and cryptographic discovery platforms.
  • Analyze cryptographic scan outputs, source code findings, certificate chains, cipher suite configurations, TLS settings, Secure Shell (SSH) settings, Open Authorization (OAuth), Security Assertion Markup Language (SAML), JSON Web Token (JWT) patterns, cloud key configurations, and key or secret storage patterns.
  • Implement and document remediation patterns approved by the Principal Architect, including hybrid TLS, proxy-based crypto agility, network encapsulation, Internet Protocol Security (IPsec), Media Access Control Security (MACsec), Key Management Interoperability Protocol (KMIP), Public-Key Cryptography Standard #11 (PKCS#11), provider libraries, custom code libraries, symmetric cryptography, Hash-Based Message Authentication Code (HMAC), TLS termination, reverse proxies, encrypted overlays, segmentation controls, compensating controls, and risk-based replacement or decommission pathways.
  • Coordinate with identity, PKI service owners, certificate management teams, cloud, infrastructure, and platform teams on certificate visibility, Certificate Lifecycle Manager (CLM) evaluation, certificate rotation, migration from manual to automated deployment, post-quantum PKI readiness, hybrid certificate testing, Certificate Authority (CA) modernization, KMS strategy, HSM patterns, secrets management, key rotation and retirement, storage standards, ownership, reporting, and centralized or federated control options.
  • Partner with Application Security, AI Security, Enterprise Architecture, Development and Operations (DevOps), and engineering teams to publish approved cryptographic libraries, secure code examples, reusable patterns, CI/CD controls, SSDLC requirements, scanning rules, developer remediation playbooks, and practical implementation guidance.
  • Apply the approved quantum risk-prioritization approach to discovery and remediation planning for business-critical applications, high-volume sensitive data flows, third-party dependencies, identity services, legacy platforms, Key Computerized Systems (KCS), validated Good x Practice (GxP) systems, and Operational Technology (OT) scope.
  • Support vendor and third-party technical governance with Procurement, Legal, Risk and Compliance, Third Party Risk Management (TPRM), and business owners by preparing technical questionnaire content, CBOM requests, evidence reviews, roadmap tracking, contract language inputs, escalation triggers, and supplier remediation follow-up.
  • Provide technical escalation and mentoring for Global Career Framework level 4 analysts and contributors, maintain cryptographic knowledge articles and implementation guides, and track changes in NIST, Internet Engineering Task Force (IETF), National Security Agency Commercial National Security Algorithm Suite 2.0 (NSA CNSA 2.0), International Organization for Standardization (ISO), Health Insurance Portability and Accountability Act (HIPAA), Health Information Trust Alliance (HITRUST), and broader industry cryptography guidance.
  • Design, implement, and govern AI-enabled process orchestration for human-intensive Encryption Agility Service workflows, including cryptographic inventory analysis, CBOM data normalization, scan output review, evidence collection, remediation tracking, reporting, and governance workflows; architect AI agents or coordinated teams of agents for data ingestion, finding correlation, false-positive triage support, ownership enrichment, remediation recommendation drafting, dashboard preparation, and knowledge article generation, while ensuring human-in-the-loop controls for risk decisions, exceptions, production changes, and final approval actions.
Desired Qualifications
  • Hands-on experience with ServiceNow Configuration Management Database (CMDB)/Governance, Risk, and Compliance (GRC), Guard, Wiz, Qualys, Fortinet, Netskope, CrowdStrike, GitLab, Veracode, GitGuardian, Amazon Web Services (AWS) KMS, AWS Certificate Manager, AWS Secrets Manager, Microsoft PKI, Sectigo, HashiCorp Vault, HSMs, CLM platforms, and Security Information and Event Management (SIEM)/data lake integrations.
  • Experience creating or operating CBOM/SBOM data models using CycloneDX 1.6+, Application Programming Interfaces (APIs), Comma-Separated Values (CSV), JavaScript Object Notation (JSON), dashboards, data quality checks, and audit-ready reporting.
  • Experience with PKI modernization, certificate automation and rotation, CA hierarchy changes, hybrid certificate testing, and Post-Quantum PKI transition support.
  • Experience with key management and secrets management across AWS, Azure, on-premises platforms, HSMs, vault technologies, automation workflows, and centralized or federated operating models.
  • Experience with application security, DevOps, SSDLC governance, CI/CD quality gates, approved cryptographic libraries, static analysis, dynamic analysis, composition analysis, and developer enablement.
  • Experience in pharmaceutical, life sciences, regulated, validated, GxP, KCS, manufacturing, OT, or other change-controlled environments.
  • Scripting and automation experience with Python, PowerShell, Bash, REST APIs, data pipelines, parsing certificate or scan data, or lightweight integration development.
  • Certified Information Systems Security Professional (CISSP); Certified Cloud Security Professional (CCSP), AWS Certified Security - Specialty, Microsoft Azure Security Engineer, or equivalent cloud security certification; Certified Information Security Manager (CISM), Certified Information Systems Auditor (CISA), or Certified in Risk and Information Systems Control (CRISC); Security+, Systems Security Certified Practitioner (SSCP), or equivalent security certification; relevant PKI, KMS, HSM, cryptographic discovery, certificate lifecycle management, cloud key management, or post-quantum cryptography training or certification.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.